The company remains in a pre-revenue stage with no commercial sales, while operating losses widened to $15.8 million in 2025Q3 due to escalating R&D expenditures.
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - | - | - |
| Operating Expenses | 28.61M | 27.97M | 12.23M | 5.45M | 12.32M | 15.64M | 10.01M | 2.18M | 1.96M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 6.52M | 6.1M | 8.7M | 3.72M | 4.25M | 4.85M | 9.81M | 1.38M | 1.11M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - |
| Research & Development | 22.1M | 21.87M | 3.53M | 1.73M | 8.07M | 10.8M | 194.01K | 800.62K | 854.11K |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -28.61M | -27.97M | -12.23M | -5.45M | -12.32M | -15.64M | -10.01M | -2.18M | -1.96M |
| Operating Margin % | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -128.74% | -124.48% | 55.77% | 21.26% | -56.33% | -359.28% | -11.06% | - |
| EBITDA | -28.58M | -27.97M | -12.22M | -5.45M | -12.32M | -15.64M | -10.01M | -2.18M | -1.96M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -86.11% | -128.95% | -124.26% | 55.77% | 21.26% | -56.33% | -359.28% | -11.06% | - |
| D&A (Non-Cash Add-back) | 34.51K | 2.06K | 12.18K | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | -28.55M | -27.97M | -12.26M | -5.45M | -12.32M | -15.64M | -10.01M | -2.18M | -1.96M |
| Net Interest Income | 269.31K | 0 | -92.19K | 150.9K | 67.47K | 5.67K | -384.22K | -295.13K | -152.1K |
| Interest Income | 269.31K | 0 | 0 | 150.9K | 67.47K | 5.67K | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 92.19K | 0 | 0 | 0 | 384.22K | 295.13K | 152.1K |
| Other Income/Expense | 327.6K | -6.07M | -122.98K | 150.9K | 67.47K | -319.33K | -341K | -295.13K | -152.1K |
| Pretax Income | -28.29M | -34.04M | -12.35M | -5.3M | -12.25M | -15.96M | -10.35M | -2.47M | -2.11M |
| Pretax Margin % | - | - | - | - | - | - | - | - | - |
| Income Tax | 29.36K | 221.1K | -503 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | -0.1% | -0.65% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -28.32M | -34.26M | -12.35M | -5.3M | -12.25M | -15.96M | -10.35M | -2.47M | -2.11M |
| Net Margin % | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -28.82% | -177.39% | -133.19% | 56.76% | 23.26% | -54.26% | -318.27% | -17.03% | - |
| Net Income (Continuing) | -28.32M | -34.26M | -12.35M | -5.3M | -12.25M | -15.96M | -10.35M | -2.47M | -2.11M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.84 | -4.32 | -12.52 | -7.05 | -27.66 | -47.90 | -52.50 | -12.80 | -10.93 |
| EPS Growth % | 39.6% | 65.5% | -77.59% | 74.51% | 42.25% | 8.76% | -310.16% | -17.11% | - |
| EPS (Basic) | - | -4.32 | -12.52 | -7.05 | -27.66 | -47.90 | -52.50 | -12.80 | -10.93 |
| Diluted Shares Outstanding | 33.54M | 8.22M | 1.03M | 751.07K | 442.8K | 333.17K | 197.08K | 193.3K | 193.3K |
| Basic Shares Outstanding | 33.54M | 8.22M | 1.03M | 751.07K | 442.8K | 333.17K | 197.08K | 193.3K | 193.3K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
Binary clinical trial failure
As indicated by recent financial disclosures, DWTX's research and development spending has surged, peaking at $14.5 million in 2025Q3, which highlights the intense capital requirements necessary to sustain late-stage clinical trial execution for its primary therapeutic candidates in the absence of any commercial revenue streams.
The dramatic spike in R&D costs during the third quarter of 2025 suggests a significant acceleration in trial-related activities, likely tied to the IMC-2 Long COVID program. Investors should monitor whether this spending level is sustainable given the company's limited cash position, as such high burn rates often necessitate dilutive financing events.
Based on reported income statements, the company continues to operate with a purely negative leverage profile, as operating losses widened to $15.8 million in 2025Q3, reflecting a lack of operational scale while the firm remains entirely dependent on external capital to fund its ongoing development activities.
The absence of revenue means that every dollar of SG&A and R&D directly impacts the bottom line, preventing any meaningful assessment of operating efficiency. The volatility in quarterly operating losses appears to be driven by the timing of clinical milestones rather than any structural improvement in overhead management.
According to historical income statement data, the company's net losses have been consistently exacerbated by high stock-based compensation and the necessity of frequent capital raises, which, as noted in recent filings, creates a significant dilution overhang that complicates the interpretation of per-share earnings metrics for investors.
The erratic nature of EPS figures, which reached a low of -$8.45 in 2025Q1, reflects the impact of both operational cash burn and the potential for equity-linked financing. Analysts should view these bottom-line figures as secondary to the company's cash runway, as the primary risk remains the potential for further equity dilution.
As evidenced by the shift in resource allocation observed in 2025, the company's transition toward the IMC-2 program represents a critical operational inflection point, marking a departure from its previous focus on fibromyalgia and signaling a high-stakes attempt to capture market interest in post-viral inflammatory syndromes.
This strategic pivot appears to be a response to the lack of commercial success or partnership interest in the IMC-1 asset. The success of this inflection remains highly speculative, as it hinges on the company's ability to successfully navigate clinical pathways for a condition with evolving diagnostic criteria.
Based on the reported $6.5 million cash balance, the company faces a precarious financial outlook, as the current burn rate suggests that existing liquidity may be insufficient to support the completion of Phase 3 trials without significant, potentially value-destructive, capital infusions in the near term.
Short-sellers would likely focus on the mismatch between the company's ambitious clinical pipeline and its rapidly depleting cash reserves. The risk of a 'going concern' qualification appears elevated, and investors should be wary of the potential for a down-round financing that could severely impair existing shareholder value.
Quick answers to the most common questions about buying DWTX stock.
For fiscal year 2025, Dogwood Therapeutics, Inc. (DWTX) reported total revenue of $0.0M.
Dogwood Therapeutics, Inc. (DWTX) reported a net loss of $34.3M for the fiscal year ending 2025.